Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press25710.17650/1726-9776-2009-5-3-29-34PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫONCOLOGICAL RESULTS OF RADICAL SURGICAL TREATMENT IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCERОНКОЛОГИЧЕСКИЕ РЕЗУЛЬТАТЫ РАДИКАЛЬНОГО ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ У ПАЦИЕНТОВ С МЕСТНО-РАСПРОСТРАНЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫLoranO. B.ЛоранО. Б.
Russian Federation
veliev@urotop.ruVeliyevE. I.ВелиевЕ. И.
Russian Federation
veliev@urotop.ruKotovS. V.КотовС. В.
Russian Federation
veliev@urotop.ruDepartment of Urology and Surgical Andrology, Russian Medical Academy of Postgraduate Education, MoscowКафедра урологии и хирургической андрологии РМАПО, Москва300920095329340308201403082014https://oncourology.abvpress.ru/oncur/article/view/257

The authors consider and prove the efficiency of radical prostatectomy used in the treatment of patients with locally advanced prostate cancer as monotherapy and as a component of multimodality therapy.

Рассмотрена и доказана эффективность применения метода радикальной простатэктомии при лечении больных местно-распространенным раком предстательной железы как в качестве монотерапии, так и как компонента мультимодальной терапии.

prostate cancerradical prostatectomyrelapse-free survivalрак предстательной железырадикальная простатэктомиябезрецидивная выживаемость1. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68—80.Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68—80.2. Schelin S., Madsen M., Palmqvist E. et al. Long-term follow-up after triple treatment of prostate cancer stage pT3. Scand J Urol Nephrol 2009;43(3):186—91.Schelin S., Madsen M., Palmqvist E. et al. Long-term follow-up after triple treatment of prostate cancer stage pT3. Scand J Urol Nephrol 2009;43(3):186—91.3. Zincke H., Bergstralh E.J., Blute M.L. et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994;12(11):2254—63.Zincke H., Bergstralh E.J., Blute M.L. et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994;12(11):2254—63.4. Palapattu G.S., Allaf M.E., Trock B.J. et al. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of longterm followup. J Urol 2004;172:1860—4.Palapattu G.S., Allaf M.E., Trock B.J. et al. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of longterm followup. J Urol 2004;172:1860—4.5. Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295—300.Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295—300.6. Pilepich M.V., Caplan R., Byhardt R.W. et al. Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG protocol 85—31. J Clin Oncol 1997;15:1013—21.Pilepich M.V., Caplan R., Byhardt R.W. et al. Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG protocol 85—31. J Clin Oncol 1997;15:1013—21.7. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103—8.Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103—8.8. Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. Engl J Med 1999;341(24):1781—8.Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. Engl J Med 1999;341(24):1781—8.9. Da Pozzo L.F., Cozzarini C., Briganti A. et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy. The positive impact of adjuvant radiotherapy. Eur Urol 2009;55(5):1003—11.Da Pozzo L.F., Cozzarini C., Briganti A. et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy. The positive impact of adjuvant radiotherapy. Eur Urol 2009;55(5):1003—11.10. Hsu C.Y., Joniau S., Oyen R. et al. Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J Androl 2009;11(1):131—7.Hsu C.Y., Joniau S., Oyen R. et al. Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J Androl 2009;11(1):131—7.11. Freedland S.J., Partin A.W., Humphreys E.B. et al. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109(7):1273—8.Freedland S.J., Partin A.W., Humphreys E.B. et al. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109(7):1273—8.12. Hsu C.Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007;51(1):121—8; discussion 128—9.Hsu C.Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007;51(1):121—8; discussion 128—9.13. Van Poppel H., Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53(2):253—9.Van Poppel H., Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53(2):253—9.14. Bader P., Burkhard F.C., Markwalder R., Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849—54.Bader P., Burkhard F.C., Markwalder R., Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849—54.15. Briganti A., Karnes J.R., Da Pozzo L.F. et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a twoinstitution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55:261—70.Briganti A., Karnes J.R., Da Pozzo L.F. et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a twoinstitution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55:261—70.16. Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54:344—52.Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54:344—52.17. Xylinas E., Drouin S.J., Comparator E. et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU Int 2009;103(9):1173—8.Xylinas E., Drouin S.J., Comparator E. et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU Int 2009;103(9):1173—8.18. Lowe B.A., Lieberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997;158(4):1452—6.Lowe B.A., Lieberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997;158(4):1452—6.19. Yamada A.H., Lieskovsky G., Petrovich Z. et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994;17(4):277—85.Yamada A.H., Lieskovsky G., Petrovich Z. et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994;17(4):277—85.20. Van der Ouden D., Hop W.C.J., Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392—7.Van der Ouden D., Hop W.C.J., Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392—7.21. Martinez de la Riva S.I., Lopez-Tomasety J.B., Dominguez R.M. et al. Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 2004;57:679—92.Martinez de la Riva S.I., Lopez-Tomasety J.B., Dominguez R.M. et al. Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 2004;57:679—92.22. Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95: 751—6.Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95: 751—6.